Kyoto University and BostonGene have launched a multicentre Phase II trial that combines immune checkpoint inhibitors with photodynamic therapy for patients with advanced gastrointestinal cancers.
Trial design and collaborators
The investigator‑initiated study is being led by Dr. Manabu Muto of Kyoto University. Financial backing comes from Meiji Seika Pharma Co., Ltd., while BostonGene contributes its AI‑driven multimodal analytics platform.
BostonGene’s system will integrate genomic, transcriptomic, immune and clinical data gathered throughout the trial. The goal is to pinpoint molecular signatures and immune‑response patterns that correlate with treatment success or resistance.
Dr. Muto said, “Applying BostonGene’s AI‑driven molecular and immune system profiling capabilities allows us to better characterise the tumor microenvironment and identify the biological features associated with durable clinical benefit.”
Potential impact on patient care
Advanced gastrointestinal cancers often leave patients with few therapeutic options. By pairing photodynamic therapy—a technique that uses light‑activated drugs to destroy tumor cells—with immune checkpoint inhibitors, the study aims to boost anti‑tumour responses.
Yukimasa Shiotsu, president of BostonGene Japan, emphasized that integrating AI‑driven multiomics analysis into clinical development is important for advancing next‑generation oncology therapeutics. He added that the partnership should clarify which patient groups stand to gain most from the combined approach.
The findings are expected to inform future trial designs, support biomarker‑driven patient selection and guide the development of combination immunotherapy regimens.
Photodynamic therapy relies on a photosensitizing agent activated by specific wavelengths of light, leading to localized tumor cell death while sparing surrounding tissue. This approach is detailed in resources about pharmacy platforms that save lives.
In practice, the trial will collect extensive data sets from each participant. BostonGene’s platform will then apply machine‑learning models to uncover patterns that might otherwise remain hidden in the complexity of multi‑omics information.
The study is still early‑stage, but its design reflects a broader trend toward data‑rich oncology research, where computational tools help translate molecular insights into actionable treatment strategies.
The success of such AI‑enhanced trials hinges on the quality of the underlying data, as well as the ability of clinicians to interpret algorithmic outputs in a clinically meaningful way. This balance between technology and bedside judgment will likely shape how similar studies evolve.
Recruitment for the Phase II trial is underway.
Participants will receive the combination therapy under close monitoring, with outcomes measured through imaging, biomarker assays and patient‑reported metrics.
The trial’s progress will be reported in peer‑reviewed journals, and interim results may be shared at oncology conferences. Should the data reveal clear benefits, the approach could be expanded to other cancer types where immune checkpoint inhibitors have shown limited efficacy.
The collaboration illustrates how academic institutions and biotech firms are leveraging artificial intelligence to accelerate the discovery of effective cancer treatments.